Updates on Clinical/Research Activities in Prostate Cancer at Stanford University

Dr. Andrei Iagaru, Professor of Radiology and Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford presented to our group about Nuclear Medicine at Stanford University and Updates on Clinical/Research Activities in Prostate Cancer on March 7, 2019.

Access the recording and presentation slides from the links below:

Clinical Trials Using Enzalutamide (Xtandi)

Enzalutamide (XTANDI) is a prescription medicine used to treat men with prostate cancer that no longer responds to a medical or surgical treatment that lowers testosterone.  XTANDI is now approved to treat men with prostate cancer that no longer responds to treatment that lowers testosterone and has not spread to other parts of the body. This is also known as non-metastatic castration-resistant prostate cancer (CRPC).

This web page, published by the National Cancer Institute, lists the clinical trials using Enzalutamide.  Click here to view the article.

Us TOO Prostate Cancer Clinical Trial Finder

The approved treatments for prostate cancer available today were made possible because patients participated in clinical trials. Through clinical trials, doctors find new and better ways to prevent, detect, diagnose, control, and treat illnesses.

However, finding an appropriate clinical trial can be challenging. We encourage you to simplify the process with The Us TOO Prostate Cancer Clinical Trial Finder, a free and confidential service that provides an efficient, user-friendly, customized approach to identify clinical trials relevant for each individual prostate cancer patient.

Read more and access the Us TOO Prostate Cancer Clinical Trial Finder